Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 22

Sort by

Sort Order Select

Journal Articles

Roneparstat (SST0001), an Innovative Heparanase (HPSE) Inhibitor for Multiple Myeloma (MM) Therapy: First in Man Study

Monica Galli, MD, Hila Magen, MD, Hermann Einsele, Manik Chatterjee, MD, Mariella Grasso, MD, Giorgina Specchia, Paola Barbieri, MD, David Paoletti, MS, Silvia Pace, MS, Ralph D Sanderson, PhD, Alessandro Rambaldi, MD, Arnon Nagler, MD MSc

Blood (2015) 126 (23): 3246.

https://doi.org/10.1182/blood.V126.23.3246.3246

Published: 2015

Journal Articles

Runx2 Transcription Factor Regulates Heparanase-Induced Bone Resorption in Multiple Myeloma

Li Nan, Haiyan Chen, Jian Ruan, MD, Rebecca S Sollie, Cara Schafer, Francis T Crittenden, Anurag Purushothaman, PhD, Ralph D. Sanderson, PhD, Amjad Javed, PhD, Yang Yang, MD, PhD

Blood (2012) 120 (21): 567.

https://doi.org/10.1182/blood.V120.21.567.567

Published: 2012

Journal Articles

Heparanase Regulates Response to Proteasomal Inhibition in Myeloma

Vishnu Prakash C. Ramani, PhD, Ralph D. Sanderson, PhD

Blood (2012) 120 (21): 4902.

https://doi.org/10.1182/blood.V120.21.4902.4902

Published: 2012

Journal Articles

Heparanase-enhanced shedding of syndecan-1 by myeloma cells promotes endothelial invasion and angiogenesis

Anurag Purushothaman, Toru Uyama, Fumi Kobayashi, Shuhei Yamada, Kazuyuki Sugahara, Alan C. Rapraeger, Ralph D. Sanderson

Blood (2010) 115 (12): 2449–2457.

https://doi.org/10.1182/blood-2009-07-234757

Published: 2010

Journal Articles

Heparanase Promotes Osteolysis by Upregulating RANKL– A Novel Role for Heparanase in Multiple Myeloma.

Yang Yang, Li Nan, Larry J Suva, Ralph D. Sanderson

Blood (2009) 114 (22): 2821.

https://doi.org/10.1182/blood.V114.22.2821.2821

Published: 2009

Journal Articles

Anti-Heparanase Therapy in Combination with Conventional Chemotherapy Potently Inhibits Multiple Myeloma Growth in Vivo

Joseph P. Ritchie, Annamaria Naggi, Giangiacomo Torri, Benito Casu, Claudio Pisano, Paolo Carminati, Israel Vlodavsky, Ralph D. Sanderson, Yang Yang

Blood (2008) 112 (11): 5165.

https://doi.org/10.1182/blood.V112.11.5165.5165

Published: 2008

Journal Articles

Heparanase Promotes the Osteolytic Phenotype in Multiple Myeloma

Yang Yang, Joseph P. Ritchie, Larry J. Suva, Ralph D. Sanderson

Blood (2008) 112 (11): 841.

https://doi.org/10.1182/blood.V112.11.841.841

Published: 2008

Journal Articles

The Heparanase Inhibitor SST0001 Is a Potent Inhibitor of Myeloma Growth In Vivo

Yang Yang, Joseph P. Ritchie, Telisha Swain, Annamaria Naggi, Giangiacomo Torri, Benito Casu, Claudio Pisano, Paolo Carminati, Israel Vlodavsky, Ralph D. Sanderson

Blood (2008) 112 (11): 246.

https://doi.org/10.1182/blood.V112.11.246.246

Published: 2008

Journal Articles

A Heparin-Based Inhibitor of Heparanase Blocks Myeloma Growth In Vivo by Targeting the Tumor Microenvironment.

Yang Yang, MD, PhD, Telisha Swain, BA, Annamaria Naggi, PhD, Giangiacomo Torri, PhD, Benito Casu, PhD, Israel Vlodavsky, PhD, Ralph D. Sanderson, PhD

Blood (2007) 110 (11): 1502.

https://doi.org/10.1182/blood.V110.11.1502.1502

Published: 2007

Journal Articles

The syndecan-1 heparan sulfate proteoglycan is a viable target for myeloma therapy

Yang Yang, Veronica MacLeod, Yuemeng Dai, Yekaterina Khotskaya-Sample, Zachary Shriver, Ganesh Venkataraman, Ram Sasisekharan, Annamaria Naggi, Giangiacomo Torri, Benito Casu, Israel Vlodavsky, Larry J. Suva, Joshua Epstein, Shmuel Yaccoby, John D. Shaughnessy, Jr, Bart Barlogie, Ralph D. Sanderson

Blood (2007) 110 (6): 2041–2048.

https://doi.org/10.1182/blood-2007-04-082495

Published: 2007

Journal Articles

Expression of Soluble Syndecan-1 or Heparanase by Myeloma Cells Enhances Levels of Angiogenic Growth Factors Present in Endothelial Cells.

Yang Yang, MD, PhD, Ashley Elizabeth Frith, Allison Theus, Veronica Macleod, MS, Ralph D. Sanderson, PhD

Blood (2006) 108 (11): 3448.

https://doi.org/10.1182/blood.V108.11.3448.3448

Published: 2006

Journal Articles

Extracellular Endosulfatases (Sulfs) Inhibit Myeloma Tumor Growth In Vivo .

Yuemeng Dai, MD, PhD, Yang Yang, MD, PhD, Veronica MacLeod, MS, Xinping Yue, PhD, Alan C. Rapraeger, PhD, Zachary Shriver, PhD, Ganesh Venkataraman, PhD, Ram Sasisekharan, PhD, Ralph D. Sanderson, PhD

Blood (2005) 106 (11): 3386.

https://doi.org/10.1182/blood.V106.11.3386.3386

Published: 2005

Journal Articles

Heparanase Upregulates Synthesis and Expression of Syndecan-1 (CD138) - A Novel Growth Regulatory Loop for Myeloma Tumors.

Yang Yang, MD, PhD, Veronica MacLeod, MS, Allison M. Theus, BS, Ralph D. Sanderson, PhD, Fenghuang Zhan, MD, PhD, John Shaughnessy, Jr., PhD

Blood (2005) 106 (11): 625.

https://doi.org/10.1182/blood.V106.11.625.625

Published: 2005

Journal Articles

Heparanase promotes the spontaneous metastasis of myeloma cells to bone

Yang Yang, Veronica MacLeod, Manali Bendre, Yan Huang, Allison M. Theus, Hua-Quan Miao, Paul Kussie, Shmuel Yaccoby, Joshua Epstein, Larry J. Suva, Thomas Kelly, Ralph D. Sanderson

Blood (2005) 105 (3): 1303–1309.

https://doi.org/10.1182/blood-2004-06-2141

Published: 2005

Journal Articles

Heparanase Promotes the Spontaneous Metastasis of Myeloma Cells to Bone.

Yang Yang, MD, PhD, Veronica MacLeod, MS, Manali Bendre, PhD, Yan Huang, Allison M. Theus, BA, Hua-Quan Miao, PhD, Paul Kussie, PhD, Shmuel Yaccoby, PhD, Joshua Epstein, DSc, Larry J. Suva, PhD, Thomas Kelly, PhD, Ralph D. Sanderson, PhD

Blood (2004) 104 (11): 635.

https://doi.org/10.1182/blood.V104.11.635.635

Published: 2004

Journal Articles

The epidermal growth factor–like domains of the human EMR2 receptor mediate cell attachment through chondroitin sulfate glycosaminoglycans

Martin Stacey, Gin-Wen Chang, John Q. Davies, Mark J. Kwakkenbos, Ralph D. Sanderson, Jörg Hamann, Siamon Gordon, Hsi-Hsien Lin

Blood (2003) 102 (8): 2916–2924.

https://doi.org/10.1182/blood-2002-11-3540

Published: 2003

Journal Articles

Osteoprotegerin is bound, internalized, and degraded by multiple myeloma cells

Therese Standal, Carina Seidel, Øyvind Hjertner, Torben Plesner, Ralph D. Sanderson, Anders Waage, Magne Borset, Anders Sundan

Blood (2002) 100 (8): 3002–3007.

https://doi.org/10.1182/blood-2002-04-1190

Published: 2002

Journal Articles

Soluble syndecan-1 promotes growth of myeloma tumors in vivo

Yang Yang, Shmuel Yaccoby, Wei Liu, J. Kevin Langford, Carla Y. Pumphrey, Allison Theus, Joshua Epstein, Ralph D. Sanderson

Blood (2002) 100 (2): 610–617.

https://doi.org/10.1182/blood.V100.2.610

Published: 2002

Journal Articles

Sperm protein 17 is expressed on normal and malignant lymphocytes and promotes heparan sulfate–mediated cell-cell adhesion

H. Marie Lacy, Ralph D. Sanderson

Blood (2001) 98 (7): 2160–2165.

https://doi.org/10.1182/blood.V98.7.2160

Published: 2001

Journal Articles

High levels of soluble syndecan-1 in myeloma-derived bone marrow: modulation of hepatocyte growth factor activity

Carina Seidel, Magne Børset, Øyvind Hjertner, Dianjun Cao, Niels Abildgaard, Henrik Hjorth-Hansen, Ralph D. Sanderson, Anders Waage, Anders Sundan

Blood (2000) 96 (9): 3139–3146.

https://doi.org/10.1182/blood.V96.9.3139

Published: 2000

NARROW

Roneparstat (SST0001), an Innovative Heparanase (HPSE) Inhibitor for Multiple Myeloma (MM) Therapy: First in Man Study

Runx2 Transcription Factor Regulates Heparanase-Induced Bone Resorption in Multiple Myeloma

Heparanase Regulates Response to Proteasomal Inhibition in Myeloma

Heparanase-enhanced shedding of syndecan-1 by myeloma cells promotes endothelial invasion and angiogenesis

Heparanase Promotes Osteolysis by Upregulating RANKL– A Novel Role for Heparanase in Multiple Myeloma.

Anti-Heparanase Therapy in Combination with Conventional Chemotherapy Potently Inhibits Multiple Myeloma Growth in Vivo

Heparanase Promotes the Osteolytic Phenotype in Multiple Myeloma

The Heparanase Inhibitor SST0001 Is a Potent Inhibitor of Myeloma Growth In Vivo

A Heparin-Based Inhibitor of Heparanase Blocks Myeloma Growth In Vivo by Targeting the Tumor Microenvironment.

The syndecan-1 heparan sulfate proteoglycan is a viable target for myeloma therapy

Expression of Soluble Syndecan-1 or Heparanase by Myeloma Cells Enhances Levels of Angiogenic Growth Factors Present in Endothelial Cells.

Extracellular Endosulfatases (Sulfs) Inhibit Myeloma Tumor Growth In Vivo .

Heparanase Upregulates Synthesis and Expression of Syndecan-1 (CD138) - A Novel Growth Regulatory Loop for Myeloma Tumors.

Heparanase promotes the spontaneous metastasis of myeloma cells to bone

Heparanase Promotes the Spontaneous Metastasis of Myeloma Cells to Bone.

The epidermal growth factor–like domains of the human EMR2 receptor mediate cell attachment through chondroitin sulfate glycosaminoglycans

Osteoprotegerin is bound, internalized, and degraded by multiple myeloma cells

Soluble syndecan-1 promotes growth of myeloma tumors in vivo

Sperm protein 17 is expressed on normal and malignant lymphocytes and promotes heparan sulfate–mediated cell-cell adhesion

High levels of soluble syndecan-1 in myeloma-derived bone marrow: modulation of hepatocyte growth factor activity

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only